Avignon

• Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised
  2022-501562-22-00 4 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Evaluation of a therapeutic de-eScalation strategy based on therapeutic drug MOnitOring in chronic non-infectious uveitis Treated witH adali … Pending
  2023-509733-39-00 6 noninfectious uveitis
• FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending
  2024-514964-24-00 5 ulcerative colitis
• Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas … Pending
  2024-515362-13-00 10 Philadelphia-negative myeloproliferative neoplasms are frequent and ch
• A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP … Pending
  2024-516570-30-00 4 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
• ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p … Pending
  2024-517285-41-00 5 Newly diagnosed prostate cancer with pelvic lymph nodes metastases
• Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractli … Pending
  2024-518251-31-00 5 patients hospitalized for a septic shock with hypercontractlity
• Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt … Pending
  2025-521199-80-00 4 Patients with previously untreated symptomatic chronic lymphocytic leu
• Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma w … Pending
  2025-521437-88-00 4 head and neck squamous cell carcinoma
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Pending
  2025-521909-40-00 4 Patients with metastatic or locally advanced HER2-low triple-negative
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management … Pending
  2025-524697-42-00 5 Pleural infections
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s … Pending
  2025-524843-11-00 4 Non-Small Cell Lung Cancer
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca … Recruiting
  2024-519901-36-00 5 2025-12-17 Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• Improving the empowerment in patients with severe breast fibrosis radio-induced treated by Pravastatin : benefit of e-PROs (electronic « Pat … Recruiting
  2024-515342-16-00 4 2024-09-05 Patients with severe and radio-induced breast fibrosis after breast ca
• ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc … Recruiting
  2023-505486-92-00 4 2024-02-09 Small bowel adenocarcinoma
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso … Recruiting
  2024-511855-16-00 5 2019-07-25 Onco-hematology
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 5 2026-05-07 Colon carcinoma

Showing 1–24 of 155 trials